Mesoblast Limited (MESO)
NASDAQ: MESO · Real-Time Price · USD
15.22
-0.11 (-0.72%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Mesoblast Revenue
Mesoblast had revenue of $51.34M in the half year ending December 31, 2025, with 1,415.41% growth. This brings the company's revenue in the last twelve months to $65.38M, up 1,053.16% year-over-year. In the fiscal year ending June 30, 2025, Mesoblast had annual revenue of $17.20M with 191.39% growth.
Revenue (ttm)
$65.38M
Revenue Growth
+1,053.16%
P/S Ratio
31.56
Revenue / Employee
$807,210
Employees
81
Market Cap
2.06B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 17.20M | 11.30M | 191.39% |
| Jun 30, 2024 | 5.90M | -1.60M | -21.32% |
| Jun 30, 2023 | 7.50M | -2.71M | -26.54% |
| Jun 30, 2022 | 10.21M | 2.78M | 37.36% |
| Jun 30, 2021 | 7.43M | -24.72M | -76.88% |
| Jun 30, 2020 | Pro | Pro | Pro |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 2.20B |
| Galapagos NV | 1.31B |
| Aurinia Pharmaceuticals | 283.06M |
| Adaptive Biotechnologies | 276.98M |
| Stoke Therapeutics | 184.42M |
| Syndax Pharmaceuticals | 172.35M |
| Zymeworks | 105.97M |
| Ocular Therapeutix | 51.95M |
MESO News
- 8 hours ago - Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain - GlobeNewsWire
- 14 days ago - Mesoblast Acquires CAR Technology From Mayo Clinic To Enhance MSC Therapies - Nasdaq
- 14 days ago - Mesoblast Secures Exclusive CAR-MSC Technology License; Stock Up - Nasdaq
- 14 days ago - Mesoblast (MESO) Secures Global License for Advanced CAR Technology - GuruFocus
- 14 days ago - Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products - GlobeNewsWire
- 18 days ago - Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION - GlobeNewsWire
- 20 days ago - Mesoblast (MESO) Gains on FDA Clearance for Duchenne Therapy Study - GuruFocus
- 20 days ago - Mesoblast Ltd Investor Day Transcript - GuruFocus